Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2954 - Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC): A European subgroup analysis


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Thyroid Cancer


Johannes Smit


Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368


J.W.A. Smit1, M.S. Brose2, F. Pitoia3, C. Lin4, I. Sugitani5, M. Alevizaki6, Y. Godbert7, J. Aller8, R.P. Peeters9, K. Pazaitou-Panayiotou10, L. Leenhardt11, M.M. Fellous12, Y. De Sanctis13, M. Schlumberger14

Author affiliations

  • 1 Department Of Medicine, Radboud University Nijmegen Medical Center, 6500 HB - Nijmegen/NL
  • 2 Department Of Otorhinolaryngology: Head And Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, 19104 - Philadelphia/US
  • 3 Department Of Endocrinology, Universidad de Buenos Aires, Buenos Aires/AR
  • 4 Department Of Oncology, National Taiwan University Hospital, Taipei/TW
  • 5 Department Of Endocrine Surgery, Nippon Medical School Graduate School of Medicine, Tokyo/JP
  • 6 Clinical Therapeutics, Alexandra Hospital, Kapodistrian University of Athens, Athens/GR
  • 7 Department Of Nuclear Medicine, Institut Bergonié, Bordeaux/FR
  • 8 Department Of Endocrinology, Hospital Puerta de Hierro Majadahonda, Madrid/ES
  • 9 Internal Medicine, Erasmus Medical Center, Rotterdam/NL
  • 10 Unit Of Endocrinology And Endocrine Oncology, Theagenio Anticancer Hospital of Thessaloniki, Thessaloniki/GR
  • 11 Department Of Thyroid Diseases And Endocrine Tumors, Pitie-Salpetriere Hospital, APHP, Paris VI University, Paris/FR
  • 12 Global Medical Affairs, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 13 Medical Writing And Statistics, Oncology Sbu, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 14 Department Of Oncology, Gustave Roussy, 94805 - Villejuif/FR


Abstract 2954


RIFTOS MKI was designed to compare the time to symptomatic progression from study entry in patients with RAI-R DTC for whom there was a decision to treat or not to treat with an MKI in the real-life setting. Here, we report interim baseline characteristics for a subgroup of patients from Europe.


RIFTOS MKI is a non-interventional study enrolling patients from USA, Japan, Europe, and rest of the world with asymptomatic RAI-R DTC. The decision to initiate MKIs at study entry was at the discretion of the treating physician. Final analysis will be performed once 700 patients have been enrolled and the last enrolled patient has been followed for 24 months.


Of the 80 patients enrolled from Europe, the median duration of observation was 165 days; 51% were male and the median age was 67 years. Most patients had an ECOG performance status of 0 or 1 (96%) and distant metastasis at initial visit (81%). The most frequent histology was papillary (61%). The median time from initial diagnosis of DTC to study entry was 7.7 years. RAI refractoriness was mainly due to lack of RAI uptake (70%) and the median time from RAI classification to initial visit was 25 months. The average dose per RAI treatment and median cumulative activity of RAI were 4.6 and 13.0 GBq, respectively.


The interim baseline characteristics results presented here are similar to those previously reported in phase III studies. The study is ongoing.

Clinical trial identification


Legal entity responsible for the study





M.S. Brose: Research funding, honoraria and consulting: Bayer F. Pitoia: Honoraria, advisory board attendance and consultancy: Genzyme/Sanofi, Bayer and AztraZeneca. I. Sugitani: Research funding: Eisai Consulting: Bayer Speaker fees: Sanofi, Bayer and Eisai. M. Alevizaki: Honoraria: Bayer and Genzyme Advisory board attendance: Sanofi. J. Aller: Advisory board attendance: Bayer, Eisai and Genzyme/Sanofi Lecture fees: Bayer, Eisai and Genzyme/Sanofi. R.P. Peeters: Honoraria: Genzyme Adboard attendance: Eisai and Genzyme. K. Pazaitou-Panayiotou: Honoraria: Novartis Advisory board attendance: Novartis. L. Leenhardt: Honoraria and speaker fees: Bayer. M.M. Fellous, Y. De Sanctis: Employee and stock ownership: Bayer. M. Schlumberger: Consulting: Bayer, Genzyme/Sanofi, Ipsen, Eisai. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.